Takeda and Frazier team up again to launch a spinout — this time focused on a late-stage vaccine
Takeda has plucked a late-stage vaccine from the pipeline and handed it to a spinout company — once again turning to some colleagues at Frazier Healthcare Partners to make the deal work.
The pharma giant is spinning out its norovirus vaccine TAK-214 to a startup called HilleVax for the last stage of what will likely be a considerable R&D journey. The world was treated to a record setting late-stage program for Covid-19 vaccines, but regular development in the field typically take years to see out.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
